Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBT Margin (2016 - 2025)

Historic EBT Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 14.45%.

  • Theravance Biopharma's EBT Margin rose 451400.0% to 14.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.81%, marking a year-over-year increase of 1232000.0%. This contributed to the annual value of 69.3% for FY2024, which is 165000.0% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's EBT Margin is 14.45%, which was up 451400.0% from 279.47% recorded in Q2 2025.
  • Theravance Biopharma's EBT Margin's 5-year high stood at 279.47% during Q2 2025, with a 5-year trough of 1589.4% in Q1 2022.
  • For the 5-year period, Theravance Biopharma's EBT Margin averaged around 226.67%, with its median value being 103.19% (2023).
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 49697800bps in 2021, then crashed by -10321200bps in 2022.
  • Theravance Biopharma's EBT Margin (Quarter) stood at 387.84% in 2021, then soared by 75bps to 97.34% in 2022, then soared by 71bps to 28.56% in 2023, then plummeted by -67bps to 47.66% in 2024, then soared by 70bps to 14.45% in 2025.
  • Its last three reported values are 14.45% in Q3 2025, 279.47% for Q2 2025, and 91.88% during Q1 2025.